StockFin.ai Try Free →

Godavari Biorefineries Limited (GODAVARIB)

Fast Moving Consumer Goods · Diversified FMCG · NSE · Updated 5 July 2026

₹272.1 ↓ 0.8% (1Y)

🎯 Key Takeaways

Godavari Biorefineries Limited is transitioning from a period of operational and financial volatility to a structured recovery phase, marked by the return to profitability and strategic scaling of high-margin bio-based chemicals and ethanol infrastructure. The company is leveraging government tailwinds in ethanol blending and industrial specialty chemicals to rebuild margins and diversify revenue streams beyond traditional sugar and bulk biofuels.
Revenue grew 39.4% QoQ to ₹447 in Q3FY25.
⚠️ Feedstock price volatility, particularly in sugar and grain inputs, continues to pressure margins despite operational resilience.

Market Cap

₹1,528

P/E Ratio

67.7

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About GODAVARIB 📊 Interactive Charts

📖 The Story

Godavari Biorefineries Limited is transitioning from a period of operational and financial volatility to a structured recovery phase, marked by the return to profitability and strategic scaling of high-margin bio-based chemicals and ethanol infrastructure. The company is leveraging government tailwinds in ethanol blending and industrial specialty chemicals to rebuild margins and diversify revenue streams beyond traditional sugar and bulk biofuels.

📰 What's Happening

In FY26, the company reported revenue of ₹2,000 crores (+6% YoY) and EBITDA of ₹139 crores (+15.8% YoY), returning to profitability with a PAT of ₹3.5 crores after prior losses. Q4 revenue reached ₹564 crores with EBITDA margin expanding to 16.2%, driven by growth in specialty chemicals (now 61% of bio-based revenue) and ethanol sales of 98 million liters. Management highlighted progress on commissioning a 200 KLPD grain-based distillery by June 2026 and plans to out-license its TNBC drug candidate within 2-3 years. Despite a sequential revenue decline to ₹570 crores in Q4 FY26 due to elevated feedstock costs, PAT remained resilient at ₹52.9 crores, reflecting operational discipline. The Board reappointed Nitin Mehta as Independent Director and Dr. Sangeeta Srivastava as Whole-Time Executive Director, ensuring leadership continuity. An earnings conference call is scheduled for May 26, 2026, to discuss these results and strategic outlook.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q2FY25	Q3FY25
Revenue	321	447
Operating Profit	-32	40
OPM %	-10.2%	8.1%
Net Profit	-75	6
EPS	₹-17.88	₹1.31

The company has reversed from losses in Q2FY25 (PAT of -₹75 crores) to profitability in FY26 (PAT of ₹3.5 crores), with EBITDA margin expanding to 16.2% in Q4. Revenue growth of 6% YoY in FY26, supported by specialty chemicals and ethanol, signals improving operational leverage. However, sequential revenue declined 3.2% in Q4 FY26 to ₹570 crores, primarily due to feedstock cost pressures, even as margins improved. This indicates that while top-line growth is being driven by strategic segments, near-term profitability remains sensitive to input cost volatility, particularly in sugar and grain-based feedstocks.

🔮 Management Outlook & What's Next

Management emphasized scaling high-margin specialty chemicals, advancing ethanol infrastructure through debottlenecking and feedstock diversification, and capitalizing on government ethanol blending policies. Key near-term milestones include commissioning of a 200 KLPD grain-based distillery by June 2026 and out-licensing of its TNBC drug candidate within 2-3 years. The company is focused on long-term value creation through R&D in antiviral and oncology platforms, with no short-term financial guidance provided beyond operational execution.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Diversified FMCG

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Hindustan Unilever Limited	5.34 L Cr	36.8	27.4%	29.4%	0.00
ITC Limited	3.88 L Cr	11.1	38.9%	50.0%	0.00
Hindustan Foods Limited	6,215	58.9	—	—	—
Godavari Biorefineries Limited	1,528	67.7	—	—	—
Rana Sugars Limited	200	5.6	—	—	—

🔗 Peer Stock Analyses

HINDUNILVR ITC HNDFDS RANASUG

⚠️ Risk Factors

1. Feedstock price volatility, particularly in sugar and grain inputs, continues to pressure margins despite operational resilience. 2. Execution risk around commissioning the 200 KLPD distillery on schedule and achieving projected margins in new segments. 3. Regulatory and policy dependence on ethanol blending targets, which, while currently supportive, remain subject to government discretion. 4. Commercialization risk of the TNBC drug candidate, where out-licensing success depends on external validation and partner uptake.

📋 Recent Filings

🧠 Analyst's Read

Godavari Biorefineries is making measurable progress in transitioning toward higher-margin bio-based chemicals and ethanol, supported by strategic investments and policy tailwinds. Investors should monitor execution of the distillery project, margin trends amid feedstock volatility, and commercial milestones in specialty chemicals and drug licensing.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on GODAVARIB

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-05.

📡 Get AI alerts when GODAVARIB files new disclosures

Track GODAVARIB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GODAVARIB — Free

Free account · No credit card · 2 AI queries/day